Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Single Dose Study With Unlabeled Dose and 14C-labeled Microdose of PF-06700841 in Healthy Male Subjects

5. marts 2019 opdateret af: Pfizer

A PHASE 1, OPEN-LABEL, NON-RANDOMIZED, 2-PERIOD, FIXED SEQUENCE STUDY TO INVESTIGATE THE ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION OF [14C-PF-06700841] AND TO ASSESS THE ABSOLUTE BIOAVAILABILITY AND FRACTION ABSORBED OF PF-06700841 IN HEALTHY MALE SUBJECTS USING A 14C-MICROTRACER APPROACH

An open-label, fixed sequence, 2-period including a single oral dose 60 mg PF-06700841 with 14C-labeled microtracer in 1st period, and a single oral dose of 60 mg unlabeled PF-06700841 followed by intravenous administration of 14C-labeled microdose of PF-06700841 1 hour after oral dose in period 2 to characterize the absorption, disposition, metabolism and excretion of PF-06700841 and evaluate the absolute bioavailability and fraction absorbed in the GI tract

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

6

Fase

  • Fase 1

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Holland
      • Groningen, Holland, 9728 NZ
        • PRA Health Sciences
      • Utrecht, Holland, 3584 BL
        • PRA Health Sciences Utrecht

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 55 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Han

Beskrivelse

Exclusion Criteria:

  • Any clinically significant malabsorption condition (eg, gastrectomy, bowel resection).
  • Total 14C radioactivity measured in plasma exceeding 11 mBq/mL
  • History of tuberculosis or active or latent or inadequately treated infection, positive QuantiFERON®-TB Gold test
  • Use of tobacoo/nicotine containing products 3-m prior to dosing or positive urine cotinine test
  • Use of herbal supplements within 28 days prior to the first dose of study medication
  • Use of prescription or nonprescription drugs (including vitamins and dietary supplements) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication. As an exception, acetaminophen may be used at doses of 1 g/day. Limited use of non-prescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case-by-case basis following approval by Pfizer
  • Inability to have at least one bowel movement every 2 days on average eGFR of <90 mL/mim/1.73 m2 based on MDRD equation
  • Have been vaccinated with live or attenuated live vaccine within the 6 weeks prior to the first dose of investigational product, or expects to be vaccinated with these vaccines during study treatment, or within the 6 weeks following the last dose of investigational product.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Grundvidenskab
  • Tildeling: Ikke-randomiseret
  • Interventionel model: Crossover opgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: 2-period, fixed sequence
fixed sequence with 2 treatment period
Medicin: Oral PF-06700841 containing 14C microtracer
Oral dose of 60 mg unlabeled PF-06700841 co-formulated with 30 ug 14C-labeled (300 nCi) PF-06700841 in 1st period
Medicin: Oral unlabeled PF-06700841
60 mg unlabeled PF-06700841 oral dose in 2nd period
Medicin: IV 14C-labeled PF-06700841
30 ug 14C-labeled (300 nCi) PF-06700841 intravenous infusion over 5 min in 2nd period

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
mass balance_urine
Tidsramme: hour 0 up to 312 hours post dose
cumulative recovery of radioactivity over time in urine, as percentage of total radioactive dose administered
hour 0 up to 312 hours post dose
mass balance_feces
Tidsramme: hour 0 up to 312 hours post dose
cumulative recovery of radioactivity over time in feces, as percentage of total radioactive dose administered
hour 0 up to 312 hours post dose

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
metabolite identification_plasma
Tidsramme: hour 0 up to 312 hours post dose
metabolic identification and profiling in plasma following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma Cmax for total 14C radioactivity
Tidsramme: hour 0 up to 312 hours post dose
maximum concentration of total 14C radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma Tmax for total 14C radioactivity
Tidsramme: hour 0 up to 312 hours post dose
time with highest concentration of radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma AUClast for total 14C radioactivity
Tidsramme: hour 0 up to 312 hours post dose
area under curve of total 14C radioactivity in plasma from time 0 to tlast following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma AUCinf for total 14C radioactivity
Tidsramme: hour 0 up to 312 hours post dose
area under curve of total 14C radioactivity in plasma from time 0 to infinite following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
Oral clearance for total 14C radioactivity
Tidsramme: hour 0 up to 312 hours post dose
oral clearance (CL/F) of total activity following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma half-life for total 14C radioactivity
Tidsramme: hour 0 up to 312 hours post dose
half-life (t1/2) of total radioactivity in plasma following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
volume of distribution for total 14C radioactivity
Tidsramme: hour 0 up to 312 hours post dose
apparent volume of distribution (Vz/F) of total radioactivity following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
plasma Cmax for PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
maximum concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma Tmax for PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
time with highest concentration of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma AUClast for PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
area under curve of PF-06700841 in plasma from time 0 to tlast following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma AUCinf for PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
area under curve of PF-06700841 in plasma from time 0 to infinite following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
Oral clearance for PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
oral clearance (CL/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma half-life for PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
half-life (t1/2) of PF-06700841 in plasma following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
volume of distribution for PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
apparent volume of distribution (Vz/F) of PF-06700841 following a single oral dose of 14C-labeled or unlabeled PF-06700841
hour 0 up to 96 hours post dose
plasma Cmax for 14C-labeled PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
maximum concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
plasma Tmax for 14C-labeled PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
time with highest concentration of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
plasma AUClast for 14C-labeled PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
area under curve of 14C-labeled PF-06700841 in plasma from time 0 to tlast following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
plasma AUCinf for 14C-labeled PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
area under curve of 14C-PF-06700841 in plasma from time 0 to infinite following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
clearance for 14C-labeled PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
clearance (CL) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
plasma half-life for 14C-labeled PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
half-life (t1/2) of 14C-labeled PF-06700841 in plasma following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
volume of distribution for 14C-labeled PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
volume of distribution (Vz/F) of 14C-labeled PF-06700841 following a single iv dose of 14C-labeled PF-06700841
hour 0 up to 96 hours post dose
unchanged PF-06700841 recovered in urine
Tidsramme: hour 0 up to 96 hours post dose
percentage of unchanged PF-06700841 recovered in urine (Ae%) following a single oral dose of PF-06700841
hour 0 up to 96 hours post dose
renal clearance of PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
renal clearance (CLr) following a single oral dose of PF-06700841 (Ae%/AUCinf for PF-06700841)
hour 0 up to 96 hours post dose
Bioavailability of oral PF-06700841
Tidsramme: hour 0 up to 96 hours post dose
Absolute bioavailability (F) following a single oral dose relative to a single iv dose of PF-06700841
hour 0 up to 96 hours post dose
Fraction absorbed of oral PF-06700841
Tidsramme: hour 0 up to 144 hours post dose
Fraction absorbed in gut (Fa) following oral dose of PF-06700841
hour 0 up to 144 hours post dose
metabolite identification_urine
Tidsramme: hour 0 up to 312 hours post dose
metabolic identification and profiling in urine following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose
metabolite identification_feces
Tidsramme: hour 0 up to 312 hours post dose
metabolic identification and profiling in feces following a single oral dose of 14C-labeled PF-06700841
hour 0 up to 312 hours post dose

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Pfizer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

10. december 2018

Primær færdiggørelse (Faktiske)

21. februar 2019

Studieafslutning (Faktiske)

21. februar 2019

Datoer for studieregistrering

Først indsendt

6. december 2018

Først indsendt, der opfyldte QC-kriterier

6. december 2018

Først opslået (Faktiske)

10. december 2018

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. marts 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. marts 2019

Sidst verificeret

1. marts 2019

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • B7931014
  • 2018-002403-34 (EudraCT nummer)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ingen

IPD-planbeskrivelse

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Sunde mandlige emner

Kliniske forsøg med Oral PF-06700841 containing 14C microtracer

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Mali

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner